In addition, a study of lymphoma pointed out that dysregulation of the GC, which result from constitutively active EZH2, activates lymphoma formation and identifies EZH2 as a possible therapeutic target for NHL and other GC-derived B-cell diseases. Here, EZH2 is linked to lymphoma.